

Rol van de pediater bij introductie van HPV vaccinatie

Prof. Jose Ramet
Diensthooft pediatrie
Universitair Ziekenhuis Antwerpen
& ZNA Koningin Paola Kinderziekenhuis



0

Rol van de kinderarts in vaccinatieschema's

- Vaccinatieschema's
 - Afhankelijk van
 - het gezondheidsbeleid van het land
 - het bestaan van pediatrie infrastructures
 - pediaters : voor adolescenten?
 - de leeftijd : start met HPV vaccinatie
 - de rol van de pediaters in het land
 - ...

1

Wie?

2

Country	HPV vaccination system in place	HPV vaccination system in development	HPV vaccination system in planning	HPV vaccination system in discussion	HPV vaccination system in research	HPV vaccination system in trial	HPV vaccination system in pilot	HPV vaccination system in evaluation	HPV vaccination system in implementation
Croatia	Yes	HPV 4E, HPV 2E, HPV 1E, HPV 3E, HPV 5E	Yes	Yes	Public health institutions (16-20) and at school (16-20) and 1 school medical specialist/500 children and adolescents	0-5-17 years	None, school health system for school children	General practitioners, pediatricians, public health institutions, family doctors	General practitioners, pediatricians, public health institutions, family doctors
Finland	Yes	HPV 2E, HPV 1E, HPV 3E, HPV 5E, HPV 4E	No	Yes	At school (7-16 years), 1 specialist/500 people, 1 doctor/100 people	7-16-17 years	School health centers, general practitioners, general pediatricians (not first of choice)	School health centers, general practitioners, general pediatricians	School health centers, general practitioners, general pediatricians
France	No	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	No	No	Outside school	16-17 years	None	General practitioners, pediatricians, public health institutions, family doctors, nurses	General practitioners, pediatricians, public health institutions, family doctors, nurses
Germany	No	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	No	No	Local health departments at school entry	2-5-17 years	None	Local health departments, general practitioners, pediatricians	Local health departments, general practitioners, pediatricians
Greece	No, but school entry medical centers are working	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	No	No	Outside school	7-11-17 years	None	General practitioners, pediatricians, public health institutions, family doctors, nurses	General practitioners, pediatricians, public health institutions, family doctors, nurses
Hungary	Yes	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	Yes	Yes	At school	7-11-14 years	School doctors, general practitioners, pediatricians	School doctors, general practitioners, pediatricians	School doctors, general practitioners, pediatricians
Italy	No, but some school health systems local vaccination systems	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	Depends on regions	Local health units	Outside school	7-5-13 years	Public health services, general practitioners, family doctors, nurses	Public health services, general practitioners, family doctors, nurses	Public health services, general practitioners, family doctors, nurses
Norway	Yes	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	Mandatory to offer, but not to accept	Yes	At school (responsibility of the municipality)	1-7-16 years	Public health services	Public health services	Public health services
Poland	Yes	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	Yes	Yes	Outside school (school departments or regional health centers)	7-5-17 years	School doctors, public health institutions, general practitioners	School doctors, public health institutions, general practitioners	School doctors, public health institutions, general practitioners
Switzerland	No (school health system at cantonal level)	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	No	Yes	At school and private sector, school health system at cantonal level of CH, various, 26 cantons of health and 26 health levels	2-12-15 years	Public health services, general practitioners, pediatricians, family doctors, nurses	Public health services, general practitioners, pediatricians, family doctors, nurses	Public health services, general practitioners, pediatricians, family doctors, nurses
Ukraine	Yes	HPV 1E, HPV 2E, HPV 3E, HPV 4E, HPV 5E	Yes	Yes	At school, public health services for schools and adolescents	6-7-16 years	Public health services, school doctors, general practitioners, pediatricians	Public health services, school doctors, general practitioners, pediatricians	Public health services, school doctors, general practitioners, pediatricians

D. FitzSimons, A. Vortsers, K. Hoppenbrouwers, P. Van Damme Vaccine 2007

In België: vaccinatie door pediaters

- Vlaanderen:
 - Zuigelingen: 11%
 - Kinderen (6j): 8%
 - uitzondering: Men C catch-up: 17-42%
 - Adolescenten (11-12j): 9%
- Wallonië:
 - Zuigelingen: 40%
 - Kinderen: geen data
 - Adolescenten: 50% door huisdokter of pediater

4

Schema? Europa?

5

Centrum voor de Evaluatie van Vaccinaties
6de Valentijn Vaccinatiesymposium - 15/02/2008

ROBERT KOCH IN
Epidemiologisches Bulletin
MINISTÈRE DE LA SANTÉ ET DES SOLIDARITÉS
DIRECTION GÉNÉRALE DE LA SANTÉ

13 landen in EU

- aanbeveling universele HPV vaccinatie
- 1^{ste} : 9-14j
- in specifieke groepen :adolescenten
- catch-up aanbevelingen: verscheidenheid

Il existe plus de 100 types de HPV. Les HPV les plus courants sont responsables de 90% des cancers du col de l'utérus et de 70% des cancers de la tête et du cou. Les HPV sont également responsables de la majorité des cancers du pénis et de la vulve. Les HPV sont également responsables de la majorité des cancers du rectum et de la gorge. Les HPV sont également responsables de la majorité des cancers du larynx et de la cavité nasale. Les HPV sont également responsables de la majorité des cancers du pharynx et de la cavité nasale. Les HPV sont également responsables de la majorité des cancers du larynx et de la cavité nasale. Les HPV sont également responsables de la majorité des cancers du pharynx et de la cavité nasale.

Recommendations in Europe

Country	Decision date	Target group	Target age	Catch-up
Austria	Jan 2007	Girls & boys	9-15y.	16-26y.
Belgium	May 2007	Girls	1 age cohort 12-15y	Up to 15y.
Denmark	Oct 2007	Girls	12 y.	13-15y. during two years as of Oct 2007
France	March 2007	Girls	14y.	15-23y.
Italy	April 2007	Girls	12y.	TBD regionally
Germany	March 2007	Girls	12-17y.	
Greece		Girls	12-15y.	15-26y.
Luxembourg	March 2007	Girls	11-12y.	13-18 y.
Spain	Sept 2007	Girls	12-13y.	TBD
Switzerland	June 2007	Girls	11-14y.	15-19y.
UK		Girls	12-13y.	TBD
Sweden		Girls	13-17y.	
Norway	April 2007	Girls	11-12y.	13-16y.

Globale perceptie van HPV: arts & patiënt

- wereldwijd
- 5,437 artsen
- kennis van HPV?

algemeen vrij laag

goed geïnformeerd?

- 71% gynecologen
- 26 % huisartsen
- 14% pediaters

Minder bekend bij artsen → minder aanbevelingen

Moorthy S. PS 1-6/ 23th international papilloma conference, Sept 1-7, 2006

Pediaters in Italië: studie in 2006

- 311 pediaters (privé, ziekenhuis, residenten)
- Anoniem : kennis & houding
- HPV vaccinatie & ziekte

Resultaten:

- Gebrek aan kennis
- 20-31%: nooit gehoord van vaccin
- 14-25%: vaccin voorkomt baarmoederhalskanker niet
 - overtuigd pediaters → mogelijk belangrijkste rol in aanbeveling vaccinatie

Besluit:


- bijscholing essentieel
- pediaters: beter informeren!

S. Esposito, et al. Vaccine 2007; 25: 6437-6446.

Ouders overtuigen?

- mijn kind – “geen risico”
- info aan hun kind: negatief effect op vroegtijdig seksueel gedrag

HPV DNA virus



- >100 types
- ~30-40 anogenitaal
 - ~15-20 oncogeenisch of hoog risico type
 - HPV 16 and HPV 18:
 - 70% van cervix kanker
 - laag risico type
 - HPV 6 and 11
 - verantwoordelijk ~90%
 - condylomata,
 - anogenitale wratten,
 - recidiverende respiratoire papillomatose

Cancers caused by HPV

Cervical Cancer	100 %
Cancer of vagina	64-91 %
Cancer of anus	88-94 %
Cancer of vulva Basaloid - warty keratinizing	60 - 90 % 4 - 7%
Cancer of penis: Basaloid - warty keratinizing	80 - 90% 10 - 20%
Cancer of oro-pharynx	35.6% (11 - 100%)
Cancer of oral cavity and larynx	23% (4 - 80%)

Munoz N et al. *Vaccine* 2006

12


Besluit

- HPV: 1 v/d meest voorkomende seksueel overdraagbare infecties
- HPV: belangrijkste oorzaak van cervix kanker bij vrouwen
- HPV: belangrijke oorzaak van andere kankers

13


Artsen & VPK overtuigen?

14



15


AGE-SPECIFIC HPV PREVALENCE AMONG WOMEN WITH NORMAL CYTOLOGY BY REGION





Samplis S. et al. *Lancet Infect Dis.* 2007;7:453-459

16

HPV-DNA PREVALENCE AND ODDS RATIOS FOR ADENO AND ADENOSQUAMOUS CARCINOMA OF THE CERVIX



17



HPV vaccin implementeren?

- Aangepaste & professionele informatie
 - artsen
 - VPK, paramedici
 - ouders & scholen
 - kinderen & adolescenten

TELL ME AND I WILL FORGET
SHOW ME AND I WILL REMEMBER
INVOLVE ME AND I WILL UNDERSTAND

20

back up

21

HPV vaccinatie

- **Gardasil®**
 - HPV 6, 11, 16, 18 + AAHS
 - Vrouw 9-26, Jongen 9-15a
 - Data voor vrouwen 25-45
 - September 2006
- **Cervarix®**
 - HPV 16, 18 + AS04
 - Vrouw 10-25a
 - Immunogenicity 10-55
 - Oktober 2007
 - Australia (up to 45)

22

Garsadil in het Belgisch staatsblad

- meisjes vanaf 12 j t&m 15 j
- publieksprijs €130,22 terugbetaling €10,60
- maximaal aantal: 3/rechthebbende
- in aanmerking voor vergoeding: ter preventie van cervix (CIN2/3), cervixkanker, hooggradige dysplasie van vulva (VIN 2/3), genitale wratten, type 6, 11, 16, 18
- tussen 12 en 15 j. 1^{ste} toediening
- voorschrift conform aan voorwaarden:
 - rekening houden met max. vergoedbare verpakkingen
 - rekening houden met leeftijd gevaccineerde
 - op voorschrift 1^{ste} - 2^{de} - 3^{de} toediening vermelden
 - bij 2^{de} en 3^{de}: datum van voorgaande vaccinatie vermelden

23